Digital Checkup (563)

Mati Gill, AION Labs CEO, provides an update on the company’s nine AI-enabled drug discovery portfolio companies, how the organizations are making an impact in life sciences and what’s next for AION, including exploring quantum technologies.

The U.S. Food and Drug Administration's validation requirements process for drug development is a good model for healthcare artificial intelligence governance, explains Michael Abrams, managing partner at Numerof & Associates.

The Philadelphia health system has committed to returning 10 million hours back to patient care over the next three years using AI, says Dr. Baligh Yehia, president of Jefferson Health.

Eitan Okun, head of the Paul Feder Laboratory for Alzheimer's Disease Research at Bar-Ilan University, discusses the lab's study on the mechanistic link between pregnancy with a Down syndrome fetus and an elevated risk of maternal cognitive decline.

CMS says about 25% of the spend is fraudulent or being abused by providers, says Carol Howard, vice president of innovation and adoption at Janus Health.

Switching cardiology patients to Bluetooth-enabled medical devices that send data to patient portals is helping to reduce chronic care complexities, says Sutter Health CCIO Dr. Richard Milani and Patient Experience R&D lead Trevor Berceau.

Electrophysiologists, who implant devices such as pacemakers, need technology to automatically determine when the billing period ends, says Sallie Gustafson, RN, director of Medical Affairs at Murj.

A Murj survey verified billing is the undisputed top concern for electrophysiologists, says Sallie Gustafson, RN, director of Medical Affairs at Murj.

Todd Van Meter, CEO of Accuity, says that when partnering with clients, initial clinical denial rates are nearly cut in half and following an appeals process using an AI-driven platform, the final denial rates end up at 1% to 1.5%.

Investments in workforce, integrated technologies will broaden and strengthen care in rural areas, says Anna Basevich, SVP at Arcadia.

Brigham Hyde, CEO of Atropos Health, discusses the rollout of its AI Evidence Agent within Microsoft Teams, which allows care teams to access real-time, patient-specific insights during meetings to drive evidence-based clinical decisions.

Kevin Ritter, EVP for CareInMotion at Altera Digital Health, offers some answers and discusses how to tackle the challenges of data fragmentation and silos that block a unified patient view and impede coordinated care.